An NCI-designated Comprehensive Cancer Center
Yan Xing

Yan Xing, M.D., Ph.D.

Medical Oncologist
Clinical Expertise
  • Solid Tumors
Appointments
Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research
Other Languages Spoken
  • Mandarin
  • Cantonese
As a physician, the goal of Yan Xing, M.D., Ph.D., is simple: to be there for her patients and their families “when they need it most.”
 
As an accomplished researcher, Dr. Xing goes further. She strives to improve cancer treatment and outcomes through rigorous data analyses to better determine which practices work best. She is also passionate about the potential of personalized medicine and new drug development, which she calls “essential to maximize the treatment outcome of cancer patients.”
 
Educated in China, Dr. Xing earned her medical degree at Sun Yat-Sen University of Medical Sciences. Upon her arrival in the U.S. she received a Ph.D. in biostatistics from the University of Texas School of Public Health. Continuing her medical training, Dr. Xing completed a fellowship in medical oncology at Houston Methodist Hospital, as well as a fellowship in Phase I Clinical Trials at MD Andersen Cancer Center.
 
Dr. Xing is delighted to be part of the City of Hope family. She appreciates the steadfast support given to the staff, and she admires the unmatched level of compassionate patient care.
 

Locations

City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

  • Xing Y, Cormier JN, Kuerer HM, Hunt KK. Sentinel lymph node biopsy following neoadjuvant chemotherapy: review of the literature and recommendations for use in patient management. Asian J Surg 27:262-7, 10/2004.
  • Cormier JN, Huang X, Xing Y, Thall PF, Wang X, Benjamin RS, Pollock RE, Antonescu CR, Maki RG, Brennan MF, Pisters PW. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol 22:4567-74, 11/2004.
  • Cormier JN, Davidson L, Xing Y, Webster K, Cella D. Measuring quality of life in patients with melanoma: development of the FACT-melanoma subscale. J Support Oncol 3:139-45, 3/2005.
  • Cormier JN, Xing Y, Ding M, Lee JE, Mansfield PF, Gershenwald JE, Ross MI, Du XL. Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy. J Clin Oncol 23:6054-62, 9/2005.
  • Vorburger SA, Xing Y, Hunt KK, Lakin GE, Benjamin RS, Feig BW, Pisters PW, Ballo MT, Chen L, Trent J, Burgess M, Patel S, Pollock RE, Cormier JN. Angiosarcoma of the breast. Cancer 104:2682-8, 12/2005.
  • Cormier JN, Xing Y, Ding M, Lee JE, Mansfield PF, Gershenwald JE, Ross MI, Du XL. Ethnic differences among patients with cutaneous melanoma. Arch Intern Med 166:1907-14, 2006.
  • Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg 93:539-46, 2006.
  • Cormier JN, Xing Y, Feng L, Huang X, Davidson L, Gershenwald JE, Lee JE, Mansfield PF, Ross MI. Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer 106:2012-20, 2006.
  • Cormier JN, Xing Y, Ding M, Cantor SB, Salter K, Lee JE, Mansfield PF, Gershenwald JE, Ross MI. Costeffectiveness of adjuvant interferon in node-positive melanoma. J Clin Oncol 25:442-48, 2007.
  • Vo T, Xing Y, Meric-Bernstam F, Mirza N, Vlastos G, Symmans WF, et al. Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg 194:527-31, 2007.
  • Anaya DA, Xing Y, Feng L, Huang X, Camacho LH, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Cormier JN. Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with micrometastatic nodal disease. Cancer 112:2030-7, 2008.
  • Askew R, Xing Y, Palmer J, Cella D, Moye L, Cormier JN. Evaluating minimal important differences for the FACT-Melanoma Quality of Life Questionnaire. Value Health. 12(8): 1144-1150, 2009.
  • Xing Y, Badgwell BD, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Cormier JN. Lymph node ratio predicts disease-specific survival in melanoma patients. Cancer 115(11):2505-13, 2009.
  • Cormier JN, Xing Y, Zaniletti I, Askew RL, Stewart BR, Armer JM. Minimal Limb Volume Change Has a Significant Impact on Breast Cancer Survivors. Lymphology, 42(4):161-175, 2009.
  • Xing Y, Chang GJ, Hu CY, Askew RL, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Cormier JN. Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer. 116(11):2234-2241, 2010.
  • Bowles TL, Xing Y, Hu CY, Mungovan KS, Askew RL, Chang GJ, Gershenwald JE, Lee JE, Mansfield PF, Yan Xing, MD, MS, PhD Ross MI, Cormier JN. Conditional survival estimates improve over 5 years for melanoma survivors with nodepositive disease. Ann Surg Oncol. 17(8):2015-2023, 2010.
  • Xing Y, Cormier JN, Shih YC T, Kapadia A, Swint J, Askew RL, Pedroza C. Bayesian bivariate analysis applied to a meta-analysis of diagnostic testing. Biostatistics, Bioinformatics and Biomathematics. 2(1):1-25, 2010.
  • Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, Royal R, Cormier JN. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients. Journal of the National Cancer Institute. 103:1-14, 2011.
  • You YN, Xing Y, Feig B, Chang G, Cormier JN. Young-onset colorectal cancer: Is it time to pay attention? Archives of Internal Medicine. 172(3):287-9, 02/2012.
  • Chagpar R, Xing Y, Chiang YJ, Feig BW, Chang GJ, You YN, Cormier JN. Adherence to stage-specific treatment guidelines for patients with colon cancer. J Clin Oncol. 30(9):972-9. 03/2012.
  • Cromwell KD, Xing Y, Ross MI, Lee JE, Gershenwald JE, Royal R, Cormier JN. Variability in melanoma posttreatment surveillance practices by country and physician specialty: A systematic review. Melanoma Research. 10/2012; 22(5):376-85.
  • Hu CY, Xing Y, Cormier JN, Chang GJ. Assessing the utility of cancer-registry-processed cause of death in calculating cancer-specific survival. Cancer 05/15/2013; 119(10):1900-7 23. Austin MT, Xing Y, Hayes-Jordan AA, Lally KP, Cormier JN. Melanoma incidence rises for children and adolescents: An epidemiologic review of pediatric melanoma in the United States. J Pediatr Surg. 11/2013; 48(11):2207-13. PMID: 24210187.
  • Massarweh N, Chiang YJ, Xing Y, Chang GJ, Haynes A, You YN, Feig BW, Cormier JN. Association between travel distance and metastatic disease at diagnosis among patients with colon cancer. J Clin Oncol. 3/20/2014; 32(9):942-8. PMID: 24516014.
  • Bedrosian I, Xing Y, Abdel Rahman S, Allen L, Le-Petross H, Whitman GJ, Meric-Bernstam F, Hunt KK, Babiera GV, Cormier JN. A Cost Analysis of Preoperative Breast MRI Use for Patients with Invasive Lobular Cancer. Ann Surg Oncol. 01/2016; 23(1):23-9. PMID: 26156655
  • Xing Y, Zhang J, Lin H, Gold KA, Sturgis EM, Garden AS, Lee JJ, William WN Jr. Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma. Cancer 02/2016; 122(4):534-45. PMID: 26554754
In The News